Trial Profile
Ocrelizumab for the Treatment of Multiple Sclerosis
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 01 Dec 2018
Price :
$35
*
At a glance
- Drugs Ocrelizumab (Primary) ; Fingolimod; Interferon beta-1a
- Indications Multiple sclerosis
- Focus Therapeutic Use
- 01 Dec 2018 New trial record
- 14 Nov 2018 Results assessing efficacy of Ocrelizumab for the treatment of Multiple Sclerosis, presented at the 21st Annual European Congress of the International Society for Pharmacoeconomics and Outcomes Research.